What Determines If Drug Use Will Be

What Determines If Drug Use Will Be

All questions are worth 20 points: What determines if drug use will be defined as drug abuse? When can the use of psychoactive chemicals be objectively labeled drug abuse? How did the changes in the marijuana-using population lead to changes in policies, like the Marijuana Tax Act? Throughout history, different drugs were introduced in the United States for purposes other than getting high, do you believe in the reasons behind this? Please give examples in your answer. Does the United States still practice this method; if so, what problems have arisen today because of this practice? What is the role of dopamine in regards to the Central Nervous System? What are the three broad categories of substances that affect the Central Nervous System? Choose one of these categories and explain how it affects the Central Nervous System.

Paper For Above instruction

Understanding the distinction between drug use and drug abuse is crucial in the context of pharmacology and public health policy. At its core, whether drug use is classified as abuse depends on several factors, including the context of use, the presence of harm or risk to health and social functioning, and the intent behind use. The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5) defines substance use disorder based on behavioral, cognitive, and physiological symptoms indicating continued use despite significant problems. This includes aspects such as compulsive use, loss of control, and adverse consequences, which help delineate abuse from recreational or medicinal use.

Objectively labeling psychoactive chemical use as drug abuse requires clear criteria that account for harmful outcomes. The key indicators include physical dependency, psychological craving, deterioration of social or occupational functioning, and legal or health-related problems directly caused by drug use. For instance, repeated use of opioids leading to addiction and health deterioration is clearly defined as abuse. Conversely, occasional recreational use without adverse consequences might not meet the criteria for abuse, despite involving psychoactive substances.

The history of drug policies in the United States illustrates how societal changes influence legislation. The increasing use of marijuana in the early 20th century, particularly among certain demographics, prompted regulatory responses such as the Marijuana Tax Act of 1937. This legislation was driven by concerns over social and racial perceptions, economic motives, and the desire to regulate drug use. The policy effectively criminalized marijuana, leading to widespread prohibition. Changes in the marijuana-using population, including increased use among different socioeconomic groups and the recognition of medicinal benefits, have since influenced reforms—culminating in the legalization and decriminalization efforts seen in various states today.

Historically, many drugs introduced into the U.S. market served purposes beyond recreational intoxication. For example, cocaine was used as a local anesthetic and stimulant medicinally, while opiates were commonly prescribed for pain relief in the 19th and early 20th centuries. These historical uses were often driven by medical needs and societal pressures, rather than solely recreational motives. The recognition of potential harms and abuse has subsequently led to tighter regulations and bans, but initial purposes underscore the dual nature of these substances as both medicinal tools and potential sources of addiction.

Despite significant regulation, some practices from the past persist today, notably the pharmaceutical industry's long-standing role in drug development and regulation. Problems arising from this include the opioid epidemic, where initially legitimate pain medications like oxycodone were overprescribed, leading to widespread addiction and societal harm. This illustrates how regulatory practices can sometimes inadvertently contribute to public health crises when oversight is insufficient or influenced by economic factors.

Dopamine plays a vital role in the central nervous system (CNS) as a neurotransmitter integral to the regulation of mood, motivation, reward, and pleasure. It is primarily produced in areas such as the substantia nigra and ventral tegmental area (VTA) of the brain. Dopamine pathways influence reinforcement learning and are heavily involved in addiction processes, as drugs that increase dopamine levels can create rewarding sensations that reinforce drug-seeking behavior. Dysregulation of dopamine signaling is also implicated in psychiatric disorders like schizophrenia and depression, highlighting its broad significance in CNS functioning.

Substances affecting the central nervous system can be categorized broadly into depressants, stimulants, and hallucinogens. Each category interacts uniquely with neural pathways, inducing different effects. For example, stimulants like cocaine and amphetamines increase synaptic dopamine levels, enhancing alertness, energy, and euphoria. They act by blocking the reuptake of dopamine into presynaptic neurons, resulting in accumulation in the synaptic cleft, which amplifies signaling and produces the characteristic stimulant effects. These drugs significantly impact CNS functioning, often leading to heightened arousal and increased risk of addiction.

References

• Anthony, J. C., & Petronis, K. R. (1995). Modeling the initiation and progression of substance use: The influence of social, environmental, and genetic factors. Annals of the New York Academy of Sciences, 778, 148–157.
• Colledge, F., & Wood, M. (2008). The Pharmacology of Drugs of Abuse. Oxford University Press.
• Estes, L. (2019). Historical perspectives on drug policy reform. Journal of Drug Policy Analysis, 12(3), 45–58.
• Gottlieb, M. (2014). The biology of addiction: Implications for treatment. Frontiers in Psychiatry, 5, 72.
• Harding, G. (2015). The evolution of drug legislation in the United States. Law and Society Review, 49(2), 341–369.
• Kandel, D. B., & Davies, M. (2001). Epidemiology of drug use and abuse. In R. M. Krueger & F. A. Hasin (Eds.), Handbook of Substance Abuse Prevention (pp. 15–34). Springer.
• Karler, R., & Turkanis, S. A. (2011). Physical and Psychological Effects of Psychoactive Substances. Elsevier.
• U.S. Department of Health and Human Services. (2016). The role of dopamine in the brain. National Institute on Drug Abuse.
• Volkow, N. D., & Morales, M. (2015). The brain on drugs: From reward to addiction. Cell, 162(4), 712–725.
• Wilkinson, G. (2018). Medicinal uses and psychoactive effects of historical drugs. Medical History, 62(2), 215–232.